Gilead Sciences, Inc.  and YM BioSciences Inc. (nyse mkt:YMI)  announced today that the companies have signed a definitive agreement under which Gilead will acquire YM for U.S.$2.95 per share in cash. The transaction has received the unanimous approval of YM's Board of Directors, and values YM at approximately U.S.$510 million.

 

Board of Directors

David G.P. Allan, Chairman of the Board